Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

Abstract

This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.